Description:

NovoRapid 100IU Vial contains the active substance Insulin Aspart, which is a rapid-acting insulin analog. It is available in vial form and is administered via subcutaneous injection. Insulin Aspart is a synthetic form of human insulin that has been modified to have a rapid onset of action and a shorter duration of activity compared to regular human insulin.

Indications:

NovoRapid 100IU Vial is indicated for the treatment of diabetes mellitus in adults and children. It is used to improve glycemic control by lowering blood sugar levels after meals. NovoRapid is commonly prescribed for individuals with type 1 diabetes, but it may also be used in combination with other insulin preparations or oral antidiabetic medications in patients with type 2 diabetes.

How It Works:

Insulin Aspart works by replacing the insulin that is normally produced by the pancreas in response to food intake. It acts rapidly to lower blood sugar levels by promoting the uptake of glucose into cells, where it is used for energy or stored for future use. Insulin Aspart has a rapid onset of action, typically within 10 to 20 minutes after injection, and reaches peak blood levels within 1 to 3 hours. Its effects last for approximately 3 to 5 hours.

Dosage and Administration:

The dosage of NovoRapid 100IU Vial is individualized based on factors such as the patient’s insulin requirements, diet, physical activity, and blood glucose levels. It is usually administered subcutaneously just before or immediately after meals to control postprandial hyperglycemia. The injection site should be rotated to prevent lipodystrophy and injection site reactions.

Possible Side Effects:

Common side effects of NovoRapid 100IU Vial may include hypoglycemia (low blood sugar), injection site reactions (such as redness, swelling, or itching), weight gain, and allergic reactions. Severe hypoglycemia can occur if the dosage of insulin is too high or if the patient skips meals or engages in excessive physical activity.

Warnings and Precautions:

1. Hypoglycemia: Patients should be educated about the signs and symptoms of hypoglycemia and instructed on how to treat it with fast-acting carbohydrates, such as glucose tablets or juice. Blood glucose monitoring is essential to prevent and detect hypoglycemia.
2. Hypokalemia: Insulin therapy can cause hypokalemia (low potassium levels) due to increased cellular uptake of potassium. Serum potassium levels should be monitored regularly, especially in patients at risk of hypokalemia (e.g., those taking diuretics).
3. Injection Site Reactions: Patients should be advised to rotate injection sites and avoid injecting into areas with signs of lipodystrophy (localized fat loss or accumulation) to minimize injection site reactions.
4. Pregnancy and Breastfeeding: Insulin requirements may change during pregnancy and breastfeeding, and close monitoring of blood glucose levels is necessary. NovoRapid can be used during pregnancy and breastfeeding under the guidance of a healthcare professional.

NovoRapid 100IU Vial is a prescription medication used for the treatment of diabetes mellitus. Patients should follow their healthcare provider’s instructions regarding dosage, administration, and monitoring of blood glucose levels. Any concerns or potential side effects should be discussed with a healthcare professional.